IP Library Granted Patent US 10,568,974
Granted Patent B2
US 10,568,974 · App. 13/624,967 · Granted Feb 25, 2020

Animal models of atherosclerosis

Inventors: Christopher S Rogers (North Liberty, IA); John R Swart (Orange City, IA)
Assignee: EXEMPLAR GENETICS LLC
A61K49/0006A01K67/0276A01K2217/075A01K2227/108A01K2267/0362
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,974
App. No.
13/624,967
Granted
Feb 25, 2020
Kind
B2
Abstract

The present invention provides transgenic, large non-human animal models of atherosclerosis and hypercholesterolemia, as well as methods of using such animal models in the identification and characterization of therapies for atherosclerosis and hypercholesterolemia.

Claims (13)

1. A transgenic Yucatan miniature pig whose genome comprises a homozygous inactivation of exon 4 in its endogenous low-density lipoprotein receptor (LDLR) gene, wherein said exon 4 comprises insertion of a gene targeting vector comprising the nucleotide sequence as set forth in SEQ ID NO: 3, wherein said pig produces no functional LDLR protein, and wherein said pig exhibits an increased level of triglycerides, LDL and VLDL cholesterol as compared to a wild type Yucatan miniature pig.

2. A transgenic Yucatan miniature pig whose genome comprises a heterozygous inactivation of exon 4 in its endogenous LDLR gene, wherein said exon 4 comprises insertion of a gene targeting vector comprising the nucleotide sequence as set forth in SEQ ID NO: 3, wherein said pig shows reduced expression of LDLR gene and an increased level of and VLDL cholesterol as compared to a wild type Yucatan miniature pig.

3. A method of making the Yucatan miniature pig of claim 2 , the method comprising:

(a) inactivation by inserting a heterologous polynucleotide comprising the nucleic acid sequence of SEQ ID NO:3 into exon 4 of the Yucatan miniature pig LDLR gene via homologous recombination in a Yucatan miniature pig fetal fibroblast;

(b) culturing the fetal fibroblast in a medium that selects for the neomycin-resistance gene for less than 20 days;

(c) introducing the nucleus of the fetal fibroblast into an enucleated Yucatan miniature pig oocyte to form a Yucatan miniature pig embryo; and

(d) transferring the Yucatan miniature pig embryo into a recipient female Yucatan miniature pig and allowing the embryo to develop such that a heterozygous transgenic Yucatan miniature pig of claim 2 whose genome comprises a heterozygous disruption of the LDLR gene is obtained.

4. The method of claim 3 , wherein the fetal fibroblast is from a male pig.

5. The method of claim 3 , wherein the fetal fibroblast is from a female pig.

6. The method of claim 3 further comprising the step of:

(e) breeding the heterozygous transgenic swine obtained in (d) such that a homozygous Yucatan miniature pig of claim 1 is obtained.

7. The method of claim 6 , wherein the fetal fibroblast is from a male pig.

8. The method of claim 6 , wherein the fetal fibroblast is from a female pig.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2012
From: SWART, JOHN R.; ROGERS, CHRISTOPHER
To: EXEMPLAR GENETICS, LLC
Reel/Frame 029155/0083 →